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Optimal Treatment of Carotid Artery Disease
Elad I. Levy, MD,*†‡ J Mocco, MD, MS,*‡ Rodney M. Samuelson, MD,*‡ Robert D. Ecker, MD,*‡
Babak S. Jahromi, MD, PHD,*‡ L. Nelson Hopkins, MD*†‡
Buffalo, New York
Extracranial carotid artery disease accounts for approximately 25% of ischemic strokes. Although carotid endar-
terectomy (CEA) is the established gold standard for carotid revascularization, carotid artery angioplasty and
stenting (CAS) is continually developing into a safer and more efficacious method of stroke prevention. Embolic
protection, improving stent designs, and ever-increasing surgeon experience are propelling CAS towards equi-
poise with and possible superiority to CEA. One multicenter randomized trial and several nonrandomized regis-
tries have successfully established CAS as an accepted treatment for high-risk patients. Clinicians must strive to
perform well-designed clinical trials that will continue to aid understanding and improve application of both en-
dovascular and open techniques for extracranial carotid revascularization. We review the data published to date
regarding the indications for and recent developments in the use of CAS. (J Am Coll Cardiol 2008;51:979–85)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.052C
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Uarotid artery angioplasty and stenting (CAS) has steadily
eveloped over the preceding decade. Current data regard-
ng CAS and carotid endarterectomy (CEA) suggest that
AS is quickly gaining ground on CEA as a first-line
reatment of extracranial carotid stenosis. Clinicians must
ontinue to refine their understanding of the appropriate
ndications for both CAS and CEA. This is done through
igorous, well-designed research. We review the data sup-
orting the implementation of CAS for extracranial athero-
cclusive carotid artery disease.
ackground
ndications for and outcomes of CEA have been extensively
tudied. The support for CEA utilization is generated from 4
ell-designed multicenter, randomized clinical trials—
ASCET (North American Symptomatic Carotid Endarter-
ctomy Trial) (1,2), ECST (European Carotid Surgery Trial)
3,4), ACAS (Asymptomatic Carotid Atherosclerosis Study)
5), and ACST (Asymptomatic Carotid Surgery Trial) (6).
he NASCET (1,2) and ECST (4) trials addressed the use of
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tenosis or selected patients with 50% to 69% stenosis. These
tudies resulted in class IA indications for the use of CEA in
ymptomatic patients meeting appropriate criteria (7). How-
ver, it is important to realize that the general population of
atients with carotid stenosis has substantially different demo-
raphics than those patients who met the strict eligibility
riteria for these studies (8). For instance, NASCET excluded
atients 80 years old and those with intracranial carotid
tenosis more severe than the surgically accessible lesion; liver,
idney, or lung failure; cardiac valve or rhythm disorder;
revious ipsilateral CEA; uncontrolled hypertension or diabe-
es; recent myocardial infarction (MI); or major surgery (1).
uch patients were considered to have excessive perioperative
orbidity (i.e., high risk). Since NASCET was published,
atients considered for carotid revascularization are often
ivided into low- and high-risk groups, and, in fact, recent
AS trial investigators have used such surgical risk stratifica-
ion as an integral part of their study design.
The ACAS (5) and the ACST (6) trials addressed the use
f CEA for asymptomatic patients. The degree of benefit
rom CEA for asymptomatic lesions is substantially less,
nd the indications for revascularization are still debated.
he ACAS and ACST trials demonstrated a 5.4% to 5.9%
bsolute risk reduction over 5 years (5,6). Therefore,
eriprocedural risks are particularly relevant to the decision
nalysis for treatment of asymptomatic patients, with a
orbidity of 3% minimizing any benefit. Despite this,
ith the publication of ACAS, nearly 75% of CEAs in the
.S. are performed on asymptomatic patients (9).
In the aforementioned trials, carefully selected low-riskatients were treated by highly experienced surgeons at
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The low complication rates seen
in NASCET and ACAS are of-
ten not obtained in the general
population. Studies have demon-
strated perioperative stroke and
death to range from 0% (10) to
11.1% (11) for symptomatic pa-
tients and 0% (12) to 5.5% (11)
for asymptomatic patients. In
fact, a study of Medicare mortal-
ity data from hospitals participat-
ing in NASCET and ACAS
demonstrated a 1.4% periopera-
tive mortality (8) compared with
.6% reported in NASCET (1) and 0.1% reported in ACAS
5). Perhaps equally concerning, CEA-related mortality
ates have been demonstrated to be higher (2.5%) for
ow-volume hospitals (8), although other studies have ar-
ued that only small differences exist between mortality
ates at high- and low-volume hospitals (13).
Treatment decisions are also dependent on patient-
pecific factors. The presence of comorbidities has signifi-
ant impact on outcome after CEA. Perioperative stroke
nd death rates for common comorbidities include conges-
ive heart failure, 8.6% (14,15); age over 75 years, 7.5%
14,15); post-endarterectomy restenosis, 10.8% (16); ipsi-
ateral carotid siphon stenosis, 13.9% (14); intraluminal
hrombus, 10.7% to 17.9% (14,17); contralateral carotid
cclusion, 14.3% (18); and CEA combined with coronary
rtery bypass grafting, 16.4% to 26.2% (19,20). It is impor-
ant to note that in the presence of such comorbidities the
atural history of carotid disease itself is more grim. The
nvestigators of the ACSRS “natural history” study followed
p 1,115 patients with asymptomatic internal carotid artery
tenosis treated with medical therapy alone (21) and iden-
ified significant differences in patient subgroups with re-
pect to stroke and death risk. The highest risk group (82%
o 99% stenosis by NASCET criteria [1], history of con-
ralateral transient ischemic attack [TIA], and serum cre-
tinine level 0.085 mmol/l) had a 4.3% annual ipsilat-
ral stroke rate compared with 0.7% in the lowest risk
roup (21,22).
It should also be noted that since the aforementioned
ajor randomized CEA trials were begun, best medical
herapy has improved. In NASCET, the primary medical
ntervention was 1,300 mg of aspirin per day (1). This dose
f aspirin is no longer used because lower doses are proven
qually efficacious with fewer side effects (23–25). Other
ntiplatelet drugs, such as clopidogrel and ticlopidine, are
lso now available (26,27); and the aspirin-dipyridamole
ombination was shown to be more efficacious than aspirin
lone (28). Methods for blood pressure control were not
pecified in NASCET, whereas it is now known that blood
ressures below 120 to 130/70 mm Hg are optimum for
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CAS  carotid artery
stenting
CEA  carotid
endarterectomy
DWI  diffusion-weighted
imaging
MI  myocardial infarction
TIA  transient ischemic
attackardiovascular risk reduction in patients with medical co- rorbidities (7,29,30) and that for primary stroke prevention
10-mm Hg reduction in systolic blood pressure produces
31% relative risk reduction for stroke (31). For secondary
troke prevention, angiotensin-converting enzyme (ACE)
nhibitors (29,32) and the combination of a thiazide diuretic
ith an ACE inhibitor (32) have now been proven effective.
dditionally, in the past decade, statins have assumed a
rominent role in cerebrovascular and cardiovascular risk
odification (33–37). In a study of patients receiving medical
reatment for severe carotid artery disease, statin use was
ssociated with significantly lower rates of stroke, MI, or death
38). It is likely that medical therapy improvement for carotid
therosclerotic disease and related comorbidities should
rompt periodic re-evaluation and risk-benefit analysis fine-
uning for medical therapy versus surgical intervention.
With the great deal of complexity regarding risk assess-
ent in this complex patient population, current standards
re limited to minimizing overall surgical risk in order to
aximize the likely benefit from surgery. Currently, the
uidelines of the American Heart Association (7) and the
anadian Neurosurgical Society (39) establish an upper
imit of 6% for perioperative risk in symptomatic patients
7) and a 3% upper limit in asymptomatic patients, assum-
ng a life expectancy of 5 years (20).
ublished Data Regarding CAS
he first randomized trial comparing endovascular and surgical
reatments for carotid stenosis patients, CAVATAS (CArotid
nd Vertebral Artery Transluminal Angioplasty Study) (40),
hich was published in 2001, included 504 patients enrolled
etween 1992 and 1997 and was designed to compare
alloon angioplasty alone versus CEA. Stents, when they
ecame available, were incorporated as well but only ac-
ounted for 26% of cases. Twenty-four centers in Europe,
ustralia, and Canada participated, and like previous CEA
rials, high-risk surgical patients were excluded from enroll-
ent—including those with recent MI, poorly controlled
ypertension or diabetes mellitus, renal disease, respiratory
ailure, inaccessible carotid stenosis, or severe cervical spon-
ylosis. The CAVATAS trial demonstrated no statistically
ignificant difference between endovascular and surgical
reatment in the rate of disabling stroke or death within 30
ays (6.4% CAS vs. 5.9% CEA) and no significant differ-
nce in the 3-year ipsilateral stroke rate. These early
ncouraging results generated a great deal of interest in
AS, and further studies were undertaken.
The Wallstent trial (41,42), the first multicenter random-
zed trial designed from inception to evaluate CEA and
AS equivalence, enrolled a total of 219 symptomatic
atients with 60% to 99% stenosis. Thirty-day stroke or
eath rates were 12.1% with CAS and 4.5% with CEA (p
.049). Additionally, 12.1% of CAS patients suffered ipsi-
ateral stroke, procedure-related death, or vascular death at
year versus 3.6% of CEA patients (p  0.022), and, as a
esult, the trial was halted by the Data Safety and Moni-
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March 11, 2008:979–85 Optimal Treatment of Carotid Artery Diseaseoring Committee after an interim analysis demonstrated
orse outcomes for the CAS group. Critical to interpreting
hese results is the fact that the Wallstent trial did not
mploy the use of distal protection devices. A significant
ortion of major CAS neurological complications are due to
theromatous material embolization (43–46). Devices that
apture embolic debris released during CAS have signifi-
antly improved procedural safety (43,46–50).
One of the first trials to utilize embolic protection was
aRESS (Carotid Revascularization Using Endarterectomy
r Stenting Systems) (51,52), a multicenter, nonrandom-
zed, prospective study comparing CAS with embolic pro-
ection (n  143) and CEA (n  254) in symptomatic
32%) and asymptomatic (68%) patients with low- and
igh-surgical risk. An important feature of CaRESS was
hat the treatment procedure was chosen by the treating
hysician and the patient, not randomized. Although this
tudy design likely introduced selection bias, the CaRESS
rial represents a generalized perspective on carotid revas-
ularization and more closely represents its ‘real world’
pplication. Baseline group demographics were similar,
xcept patients with previous carotid intervention more
ften received CAS. No statistically significant difference
etween 30-day and 1-year death or stroke rates existed
etween CAS and CEA (2.1% vs. 3.6% and 10.0% vs.
3.6%, respectively), nor did significant differences exist for
estenosis, residual stenosis, repeat angiography, and need
or carotid revascularization. Overall morbidity and mortal-
ty approached NASCET (1,2) and ACAS (5) standards
nd represented the lowest rates among the major CAS
rials to date. The low stroke and death rates may be
ttributable to the ability of the treating physician to
onsider patient-specific factors and successfully assign each
atient to the safest therapy.
Carotid artery stenting was well established as a treat-
ent option for high-risk patients by SAPPHIRE (Stent-
ng and Angioplasty with Protection in Patients at High
isk for Endarterectomy) (53), a randomized, multicenter
rial to determine CAS noninferiority to CEA in high-risk
atients. Eligible patients (n  344) had symptomatic
tenosis of at least 50% or asymptomatic stenosis of at least
0%. The 30-day MI, stroke, or death rate was 4.8% for
AS and 9.8% for CEA (p 0.09). Much of this difference
as secondary to MIs in the CEA group, and although not
eported in SAPPHIRE, the 30-day rate of stroke and
eath was 4.8% for CAS patients and 5.6% for CEA
atients. At 1 year, 12.2% of CAS patients had suffered
troke, MI, or death versus 20.1% of CEA patients (non-
nferiority analysis: p  0.004; superiority analysis:
ntention-to-treat p  0.053, as-treated p  0.048). Myo-
ardial infarction and major ipsilateral stroke rates were
ignificantly better after CAS versus CEA (2.5% vs. 8.1%,
 0.03; 0% vs. 3.5%, p  0.02; respectively).
As SAPPHIRE had shown such clear noninferiority in
igh-risk patients, the SPACE (Stent-supported Percuta-
eous Angioplasty of the Carotid artery versus Endarterec- romy) trial (54) set out to establish noninferiority for CAS
ompared with CEA in patients with low risk. A multi-
enter trial, SPACE compared safety and efficacy of CAS
nd CEA in 1,183 randomized patients with symptomatic
arotid artery stenosis (70% by duplex ultrasonography,
50% by NASCET criteria [1], or70% by ECST criteria
3]). The 30-day rates of ipsilateral stroke or death were
.84% for CAS and 6.34% for CEA (p value not significant)
54). It is important to note that embolic protection was not
equired and was only used in 27% of cases, though a
ubgroup analysis did not demonstrate a significant differ-
nce between patients with embolic protection versus those
ithout. Despite these encouraging results, “SPACE failed
o prove the noninferiority of carotid-artery stenting” (54)
tatistically. This is because the trial was halted more than
00 patients shy of its goal enrollment of 1,900 patients as
he result of an interim analysis demonstrating that 2,500
atients would be needed to reach significance given the
esults up to that point. The Steering Committee acknowl-
dged a “lack of funds” (54) to expand the trial to an
nrollment of 2,500 patients and therefore halted the trial.
n essence, the study was underpowered to demonstrate
oninferiority due to incorrect estimation of the anticipated
ffect sizes. Still, although its a priori goals were not
ealized, the observed 0.51% difference in perioperative
troke or death between CAS and CEA was not statistically
ignificant and is well within the published differences
etween individuals, institutions, and variations of CEA.
The results mentioned in the preceding text, although
hey were negative, were still quite encouraging to CAS
roponents. Unfortunately, a second multicenter, random-
zed trial to assess the noninferiority of CAS versus CEA in
atients with 60% stenosis, EVA-3S (Endarterectomy
ersus Angioplasty in Patients with Symptomatic Severe
arotid Stenosis), was ended after interim analysis (n 
27) demonstrated a 30-day rate of any stroke or death to be
ignificantly higher in the CAS group (9.6%) than the CEA
roup (3.9%) (p 0.01) (55). Importantly, early in the trial,
he use of embolic protection was not required. Patients
reated without embolic protection experienced a 25%
0-day rate of stroke or death (5 of 20 patients), prompting
rotocol changes by the EVA-3S safety committee. Addi-
ionally, EVA-3S compared groups of physicians with
nequal experience. Surgeons performing CEA had per-
ormed at least 25 endarterectomies in the year before trial
ntry, yet endovascular physicians were certified after com-
leting as few as 5 to 12 CAS procedures (5 CAS among at
east 35 stent procedures to supra-aortic vessels or 12 CAS).
ndovascular physicians were also allowed to enroll study
atients while simultaneously undergoing training and cer-
ification. Subgroup analysis based upon CAS physician
xperience demonstrated a 12.3% stroke and death rate
mong endovascular physicians tutored in CAS during the
rial (55), compared with 7.1% among those tutored in CAS
uring their endovascular training and 10.5% among expe-
ienced CAS physicians. The resulting overall rate of stroke
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Optimal Treatment of Carotid Artery Disease March 11, 2008:979–85nd death (9.6%) is substantially higher than in other
andomized trials. Therefore, it is hard to accept such an
levated complication rate as representative of the practice
f CAS in general. It is more likely that EVA-3S empha-
izes the importance of embolic protection as well as
igorous training and credentialing for CAS physicians. The
mplied importance in EVA-3S of embolic protection has
een further supported by numerous radiologic studies
xamining the frequency of (mostly small, asymptomatic)
schemic (DWI [diffusion-weighted imaging]) lesions on
ost-operative magnetic resonance imaging. These studies
ave demonstrated the following: a reduction in the fre-
uency of DWI lesions with distal embolic protection (49%
s. 67%) (48) and fewer DWI lesions after CEA than CAS
11.6% vs. 42.6%, no significant clinical difference) with
urrent embolic protection devices (56), and a low frequency
f DWI lesions with more recent embolic protection de-
ices, such as the NeuroProtection System (W.L. Gore &
ssociates, Flagstaff, Arizona) (57), at a rate not signifi-
antly different from that incurred by diagnostic cerebral
ngiography alone (18.2% vs. 11.5%) (58).
Carotid registries (CABERNET [Carotid Artery Revascu-
arization using the Boston Scientific FilterWire EX/EZ and
he EndoTex NexStent], ARCHeR [ACCULINK for Revas-
ularization of Carotids in High-Risk patients], CREATE
Carotid Revascularization with ev3 Arterial Technology Evo-
ution], CAPTURE [Carotid Acculink/Accunet Post Ap-
roval Trial to Uncover Unanticipated or Rare Events],
EACH [Boston Scientific EPI: A Carotid Stenting Trial for
igh-Risk Surgical Patients], CASES-PMS [Carotid Artery
tenting with Emboli protection Surveillance—Post Market-
ng Study], and ALKK [Arbeitsgemeinschaft Leitende Kardi-
logische Krankenhausarzte]) are nonrandomized outcome
ecords for symptomatic and asymptomatic high-risk CAS
atients. Although registries do not provide direct comparison
ata, they do help establish true adverse event rates in high-risk
AS patients and are a crucial component in improving our
nderstanding concerning the risks of CAS. The collaborators
f CABERNET (n 462 patients) found a 3.9% 30-day rate
f stroke or death (59), whereas the investigators of ARCHeR
n 581 patients) found a 30-day stroke or death rate of 6.9%
s well as a 1-year composite outcome (30-day rate of MI,
troke, or death plus the 1-year rate of ipsilateral stroke) of
.6% (60). The CREATE registry (n  419 patients) dem-
nstrated a 6.2% 30-day rate of MI, stroke, and death (61).
he CAPTURE registry (n  3,500) determined that post-
AS incidence of stroke, MI, and death was 6.3% for patients
reated with the Acculink/Accunet CAS system (Abbott Vas-
ular, Santa Clara, California), as well as a rate of major stroke
r death of 2.9% (62,63). The BEACH investigators (n 747
atients) found a 30-day MI, stroke, or death rate of 5.8% (64).
hese results were similar to those in the CASES-PMS
egistry (5.0%), which examined the use of distal protection by
ndovascular carotid surgeons who either had previous experi-
nce with the device (Angioguard XP, Cordis Endovascular,iami Lakes, Florida) or who underwent formal training (n a,493) (65). Under these rigorous conditions, the 30-day major
dverse event rate did not vary significantly between symptom-
tic and asymptomatic patients and among physicians with
igh- and low-volume or differing level of experience with the
pecific distal protection device. The German ALKK registry
n  1,888 patients), which included patients with standard
isk, demonstrated an in-hospital death and stroke rate of 3.8%
66). Interestingly, when this risk was stratified by time, the
nvestigators saw improvement from 6.3% in 1996 to 1.9% in
004 (p  0.021). Continued effort to maintain rigorous
egistries like the above are critical to our eventual understand-
ng of appropriate patient selection and procedural risks.
urrent Trials
he 2 major ongoing, randomized trials of CAS versus
EA are CREST (Carotid Revascularization Endarterec-
omy versus Stent Trial) and ICSS (International Carotid
tenting Study). The CREST trial is an ongoing, National
nstitutes of Health-funded, multicenter randomized trial
eeking to enroll 2,500 patients with 50% symptomatic
arotid stenosis or 70% asymptomatic stenosis for ran-
omization to CEA or CAS. Primary end points include
eath, stroke, or MI at 30 days, and ipsilateral stroke within
0 days. The CREST trial maintains a rigorous credential-
ng phase for CAS providers (67), requiring up to 20
onitored procedures. During its lead-in phase, CREST
emonstrated a 4.6% 30-day stroke and death rate, with
I, stroke, and death rates of 5.7% for symptomatic
atients and 3.5% for asymptomatic patients. Similar stroke
nd death rates were observed for both men and women
68), as well as those treated with or without embolic
rotection (69). However, patients 80 years (70,71) expe-
ienced a 30-day stroke and death rate of 12.1%, signifi-
antly higher than for patients age 60 to 69 years (1.3%) and
0 to 79 years (5.3%) (p  0.0006) (70).
The ICSS study resulted from the favorable results of
AVATAS and is also known as CAVATAS-2 (72). It is
multinational prospective trial randomizing symptomatic
atients equally suited for CAS or CEA. Additionally,
essons learned from EVA-3S are being applied. Atten-
ance at a CAS training course is required, as well as
andatory proctoring for centers with limited experience
dmitted to the trial on a probationary status. Further,
mbolic protection is recommended whenever the endovas-
ular physician believes a protection device can be safely
eployed.
An additional ongoing study is ACT I (Asymptomatic
arotid Stenosis, Stenting versus Endarterectomy Trial), a
andomized trial of low-risk patients with asymptomatic
0% to 99% carotid stenosis at multiple centers across North
merica (73,74). The primary outcomes will be 30-day MI,
troke, and death rates and 5-year stroke-free survival. The
ACIT (Transatlantic Asymptomatic Carotid Intervention
rial) will randomize standard- and high-risk patients withsymptomatic carotid stenosis into 1 of 3 treatment arms:
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March 11, 2008:979–85 Optimal Treatment of Carotid Artery Diseaseptimal medical therapy only (antiplatelet, antilipidemic,
ntihypertensive, strict diabetes control, and smoking ces-
ation), optimal medical therapy plus CEA, or optimal
edical therapy plus CAS with embolic protection (75,76).
lanned enrollment is 2,400 patients with a primary end
oint of stroke and death occurrence at 3 years. Secondary
nd points include rates of TIA and MI, economic cost,
uality-of-life analysis, neurocognitive function, and carotid
estenosis. Continued effort and the eventual completion of
hese trials will improve our understanding of the relative
ndications and contraindications of CAS and CEA.
ptimal Treatment Selection
iven the existence of surgical and endovascular therapies
or patients with carotid stenosis, optimal treatment selec-
ion for each given patient will be the eventual method by
hich the lowest morbidity rates with the most favorable
utcomes are achieved. Fundamental to treatment selection
s an understanding of the demographics used to categorize
atients as high risk. High-risk demographics are previously
efined in large surgical studies, such as NASCET (1) and
CAS (5). These demographic criteria include:
Anatomical: 1) restenosis after CEA; 2) contralateral
occlusion; 3) previous neck radiation or surgery; 4)
surgically inaccessible lesions (e.g., located above the
C-2 level, below the clavicle); 5) neck immobility; 6)
tracheostomy; 7) contralateral laryngeal palsy; 8) bi-
lateral severe stenotic lesions requiring treatment; and
9) severe intracranial stenosis.
Medical comorbidities: 1) unstable angina; 2) poor
cardiac ejection fraction; 3) congestive heart failure; 4)
planned coronary artery bypass operation; 5) obstruc-
tive pulmonary disease; and 6) advanced age (75 or
80 years, depending on the trial).
Given the continually mounting evidence, it appears
ppropriate to offer CAS over CEA to all patients
eeting the above high-risk categorizations, symptom-
tic or asymptomatic. However, whether patients do or
o not strictly meet the above criteria, other characteris-
ics need to be taken into account. For instance, patients
ith heavily calcified plaques, a complex aortic arch,
xcessively tortuous vessels, or internal carotid arteries
ith lumen diameters smaller than 3 mm are likely better
erved with endarterectomy (77– 85). This is because
eavily calcified plaques often result in insufficient endo-
ascular revascularization secondary to their being refrac-
ory to balloon remodeling; loops and significant vessel
ortuosity make stable guide catheter placement as well as
lter and stent deployment excessively difficult, and
umen diameters smaller than 3 mm do not safely
ccommodate most distal protection devices.onclusions
arotid artery stenting is continually developing into a safer
nd more efficacious therapy for extracranial carotid artery
tenosis. The greater weight of the evidence, as confirmed in
Cochrane review (86), suggests no significant difference
etween CAS and CEA. However, CAS is still a burgeon-
ng technology with many questions still needing to be
nswered. Future clinical research should address many of
hese questions. As we move towards the future, the
uestion posed should now be “what is the optimal treat-
ent for carotid artery stenosis in this patient?” not “what is
he optimal treatment for carotid artery stenosis?” Endovas-
ular physicians must rigorously apply the lessons learned
rom previous well-designed trials to avoid treating patients
ho are at higher risk for complications with CAS. Con-
inued enrollment in rigorously randomized trials such as
REST will provide a great deal of insight into such
atient-specific risk factors. The use of CAS and CEA as
omplementary therapies, while optimizing current medical
reatments, will provide the greatest likelihood of minimiz-
ng poor patient outcomes.
eprint requests and correspondence: Dr. Elad I. Levy, Univer-
ity at Buffalo Neurosurgery, Millard Fillmore Gates Hospital, 3
ates Circle, Buffalo New York 14209. E-mail: elevy@buffns.com.
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